Short Interest in Adhera Therapeutics, Inc. (OTCMKTS:ATRX) Declines By 95.0%

Adhera Therapeutics, Inc. (OTCMKTS:ATRX) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 100 shares, a drop of 95.0% from the February 29th total of 2,000 shares. Based on an average daily trading volume, of 220,800 shares, the days-to-cover ratio is presently 0.0 days.

Adhera Therapeutics Price Performance

Shares of OTCMKTS:ATRX opened at $0.01 on Thursday. The company has a 50 day moving average of $0.02 and a two-hundred day moving average of $0.02. Adhera Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.60.

About Adhera Therapeutics

Adhera Therapeutics, Inc, a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc and changed its name to Adhera Therapeutics, Inc in October 2018.